[go: up one dir, main page]

ES2121084T3 - Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos. - Google Patents

Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.

Info

Publication number
ES2121084T3
ES2121084T3 ES93909249T ES93909249T ES2121084T3 ES 2121084 T3 ES2121084 T3 ES 2121084T3 ES 93909249 T ES93909249 T ES 93909249T ES 93909249 T ES93909249 T ES 93909249T ES 2121084 T3 ES2121084 T3 ES 2121084T3
Authority
ES
Spain
Prior art keywords
patient
hydrogen
antihistaminics
hepatic disorders
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909249T
Other languages
English (en)
Inventor
James K Woodward
Richard R Okerholm
Mark G Eller
Bruce E Mcnutt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2121084(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2121084T3 publication Critical patent/ES2121084T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA PROPORCIONAR UN EFECTO ANTIHISTAMINICO EN UN PACIENTE DAÑADO HEPATICAMENTE QUE LO NECESITE, Y QUE CONSISTE EN ADMINISTRAR A DICHO PACIENTE UNA CANTIDAD ANTIHISTAMINICA EFECTIVA DE UN COMPUESTO DE LA FORMULA (I) EN LA QUE R1 ES HIDROGENO O HIDROXI; R2 ES HIDROGENO; O R1 Y R2 JUNTOS FORMAN UN SEGUNDO ENLACE ENTRE LOS ATOMOS DE CARBONO QUE LLEVAN R1 Y R2; N ES UN ENTRE DE 1 A 5; R3 ES -COOH O -COOALKILO EN DONDE LA UNIDAD DE ALKILO TIENE DE 1 A 6 ATOMOS DE CARBONO Y ES DE CADENA RECTA O RAMIFICADA; CADA A Y B ES HIDROGENO O HIDROXI SIEMPRE Y CUANDO AL MENOS UNO DE ENTRE A Y B SEA HIDROGENO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE E ISOMEROS INDIVIDUALES DEL MISMO.
ES93909249T 1992-05-11 1993-04-06 Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos. Expired - Lifetime ES2121084T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88080192A 1992-05-11 1992-05-11
US92289092A 1992-07-31 1992-07-31

Publications (1)

Publication Number Publication Date
ES2121084T3 true ES2121084T3 (es) 2002-02-16

Family

ID=27128589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909249T Expired - Lifetime ES2121084T3 (es) 1992-05-11 1993-04-06 Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.

Country Status (16)

Country Link
US (7) US6037353A (es)
EP (1) EP0639976B1 (es)
JP (1) JPH07506828A (es)
KR (1) KR950701525A (es)
AT (1) ATE194913T1 (es)
AU (1) AU679910B2 (es)
CA (1) CA2134211C (es)
CL (1) CL2004000304A1 (es)
DE (1) DE69320952T2 (es)
DK (1) DK0639976T3 (es)
ES (1) ES2121084T3 (es)
HU (1) HU223774B1 (es)
MX (1) MX9302704A (es)
NO (1) NO307688B1 (es)
NZ (1) NZ251834A (es)
WO (1) WO1993023047A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679910B2 (en) * 1992-05-11 1997-07-17 Merrell Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
DK0701443T4 (da) † 1992-08-03 2000-12-18 Sepracor Inc Terfenadinmetabolitter og deres optisk rene isomerer til behandling af allergiske lidelser
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
IT1271417B (it) * 1993-10-15 1997-05-28 Erregierre Ind Chim Composti ad attivita' antiistaminica procedimento per la loro preperazione e composizioni farmaceutiche che li contengono.
EP0766668B1 (en) * 1994-05-18 2002-07-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2213700C (en) 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
PT998272E (pt) * 1997-08-26 2003-09-30 Aventis Pharma Inc Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003104197A1 (en) * 2002-06-10 2003-12-18 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
EP1393728A1 (en) * 2002-08-30 2004-03-03 Vrije Universiteit Inverse agonists acting at virus-encoded G protein-coupled receptors
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
JP2007532687A (ja) * 2004-04-26 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド フェキソフェナジン塩酸塩の結晶形およびその製造方法
EP1685106A2 (en) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadine crystal form and processes for its preparation thereof
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
KR20110017365A (ko) * 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
AU679910B2 (en) * 1992-05-11 1997-07-17 Merrell Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
DK0701443T4 (da) * 1992-08-03 2000-12-18 Sepracor Inc Terfenadinmetabolitter og deres optisk rene isomerer til behandling af allergiske lidelser

Also Published As

Publication number Publication date
US6187791B1 (en) 2001-02-13
NO944287D0 (no) 1994-11-10
DE69320952D1 (de) 1998-10-15
US6037353A (en) 2000-03-14
DK0639976T3 (da) 1999-02-15
EP0639976B1 (en) 2000-07-26
EP0639976A1 (en) 1995-03-01
US20100168166A1 (en) 2010-07-01
US20060205782A1 (en) 2006-09-14
JPH07506828A (ja) 1995-07-27
KR950701525A (ko) 1995-04-28
AU3973493A (en) 1993-12-13
MX9302704A (es) 1994-06-30
US6399632B1 (en) 2002-06-04
AU679910B2 (en) 1997-07-17
NO944287L (no) 1994-11-10
WO1993023047A1 (en) 1993-11-25
HU223774B1 (hu) 2005-01-28
CL2004000304A1 (es) 2005-05-27
CA2134211A1 (en) 1993-11-25
DE69320952T2 (de) 1999-05-27
NO307688B1 (no) 2000-05-15
NZ251834A (en) 1997-07-27
HUT71402A (en) 1995-11-28
CA2134211C (en) 1999-06-29
US20030130315A1 (en) 2003-07-10
US20030055083A1 (en) 2003-03-20
ATE194913T1 (de) 2000-08-15

Similar Documents

Publication Publication Date Title
ES2121084T3 (es) Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.
CA2362337A1 (en) Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
ES2126068T3 (es) Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene.
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
SE8002634L (sv) Piperidinderivat
FR2662162B1 (fr) Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ES2091057T3 (es) Composicion medicinal que mejora el metabolismo de los lipidos.
FR2613365B1 (fr) Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
ES2148305T3 (es) Derivados de aminoacidos ciclicos que tienen actividad inhibidora de ace y nep.
DE69315827D1 (de) Neue acylierte phospholipid-arzneimittel
TR199902350T2 (xx) Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler.
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE172959T1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
EP0760375A4 (en) Antitumor indolopyprolocarbazole derivative
ES2058315T3 (es) Compuestos eficaces contra insuficiencia cerebral.
TW353071B (en) Chromene compounds with neutroleptic activity, their preparation and pharmaceutical compositions
ES2102466T3 (es) Nuevos compuestos denominados adenofostinas; su preparacion y su uso terapeutico.
HN1999000026A (es) Biciclo (2.2.1) heptanos y compuestos relacionados.
IT1250626B (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639976

Country of ref document: ES

FG2A Definitive protection

Ref document number: 639976

Country of ref document: ES